Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XOMA RoyaltyXOMA -0.10%41 Receivables Turnover is 0.07 as of Mar. 2026. GuruFocus rates XOMA with a GF Score™ of 41/100 and a GF Value™ of $18.97 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 841 Biotechnology companies, XOMA Royalty ranks worse than 85.49% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. XOMA Royalty's Revenue for the
three
months ended in Mar. 2026 was $0.31 Mil. XOMA Royalty's average Accounts Receivable for the
three
months ended in Mar. 2026 was $4.75 Mil.
Hence, XOMA Royalty's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.07.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
XOMA Royalty Receivables Turnover Related Terms
XOMA Royalty Receivables Turnover Historical Data
* Premium members only.
The historical data trend for XOMA Royalty's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XOMA vs STTK, OMER, BBOT: Receivables Turnover Comparison
For the Biotechnology subindustry, XOMA Royalty's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XOMA Royalty Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XOMA Royalty's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where XOMA Royalty's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XOMA Royalty (XOMA) has a Receivables Turnover of 0.07 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on XOMA Royalty and its competitors. According to the industry distribution chart, XOMA Royalty ranks #719 out of 841 companies in the Biotechnology industry, placing it in the top 85.5%.
Is XOMA Royalty's Receivables Turnover too high?
XOMA Royalty's current Receivables Turnover is 0.07. The Biotechnology industry median Receivables Turnover is 5.29. XOMA Royalty's value of 0.07 is 98.7% below this industry median. Based on the distribution chart, XOMA Royalty ranks #719 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XOMA Royalty has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's Receivables Turnover compare to STTK and OMER?
According to the Biotechnology industry distribution chart, XOMA Royalty ranks #719 out of 841 companies for Receivables Turnover. This places XOMA Royalty in the lower half of its industry. The industry median Receivables Turnover is 5.29. XOMA Royalty's value of 0.07 is 98.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XOMA Royalty's current Receivables Turnover of 0.07 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on XOMA Royalty and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XOMA Royalty's current Receivables Turnover is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.97, compared to a current price of $40.17 — trading 111.8% above its estimated fair value. The current Receivables Turnover is 0.07 and 98.7% below the Biotechnology industry median of 5.29. XOMA Royalty's overall GF Score™ is 41/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current Receivables Turnover is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XOMA Royalty (XOMA) Overvalued in 2026?
Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued.
The current stock price of $40.17 is trading 111.8% above its estimated GF Value™ of $18.97.
GuruFocus considers XOMA Royalty to be Significantly Overvalued.
Key valuation signals for XOMA:
Receivables Turnover: 0.07
GF Value™: $18.97 vs. price of $40.17 (111.8% above fair value)
Industry Position: 98.7% below the Biotechnology median (#719 of 841)
No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
41GF Score
Get the complete analysis for XOMA
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XOMA has been successfully added to your 
